Information
71 Techno 2-ro, Yuseong District, Daejeon, South Korea
+82 42-930-8600
-
-
Overview
- Summary
- Bioneer, established in 1992 as Korea's first biotech venture, is a comprehensive biotechnology company providing molecular biology research products, molecular diagnostic systems, RNAi-based drug development, and microbiome healthcare solutionsBioneer, established in 1992 as Korea's first biotech venture, is a comprehensive biotechnology company providing molecular biology research products, molecular diagnostic systems, RNAi-based drug development, and microbiome healthcare solutions
- Key Products/Technologies
- High-quality oligo supply capabilities through DNA/RNA oligonucleotide chemical synthesis services and patented AccuOligo® technologyHigh-quality oligo supply capabilities through DNA/RNA oligonucleotide chemical synthesis services and patented AccuOligo® technology
- Development of various gene amplification instruments including thermostable DNA polymerases, PCR, RT-PCR, Real-Time qPCR reagents, AllInOneCycler™, and Exicycler™Development of various gene amplification instruments including thermostable DNA polymerases, PCR, RT-PCR, Real-Time qPCR reagents, AllInOneCycler™, and Exicycler™
- Provision of automated nucleic acid extraction instruments ExiPrep™ series (ExiPrep™ 16, 48, 96 Lite) and DNA/RNA extraction kits for various samplesProvision of automated nucleic acid extraction instruments ExiPrep™ series (ExiPrep™ 16, 48, 96 Lite) and DNA/RNA extraction kits for various samples
- Development of ExiStation™ series (ExiStation™ V4, 48, FA 96/384) molecular diagnostic systems, automating the entire process from nucleic acid extraction to gene amplification and analysisDevelopment of ExiStation™ series (ExiStation™ V4, 48, FA 96/384) molecular diagnostic systems, automating the entire process from nucleic acid extraction to gene amplification and analysis
- RNAi drug development capabilities utilizing the supramolecular siRNA nanostructure SAMiRNA™ platform technologyRNAi drug development capabilities utilizing the supramolecular siRNA nanostructure SAMiRNA™ platform technology
- Provision of mRNA synthesis and protein synthesis/purification services through ExiProgen™, the world's first automated protein synthesis and purification systemProvision of mRNA synthesis and protein synthesis/purification services through ExiProgen™, the world's first automated protein synthesis and purification system
- Development and commercialization of functional probiotic products for body fat reduction based on the patented anti-obesity lactic acid bacterium BNR17®Development and commercialization of functional probiotic products for body fat reduction based on the patented anti-obesity lactic acid bacterium BNR17®
- Launch of COSMERNA®, the world's first siRNA hair loss relief cosmetic applying SAMiRNA™ technologyLaunch of COSMERNA®, the world's first siRNA hair loss relief cosmetic applying SAMiRNA™ technology
- Core Advantages
- A vertically integrated business structure, from raw materials to final products, developed, produced, and supplied in-house, aiming for complete localization of genetic technologyA vertically integrated business structure, from raw materials to final products, developed, produced, and supplied in-house, aiming for complete localization of genetic technology
- Development of numerous world-first and Asia-first innovative products, including 384-oligo simultaneous automatic synthesizer, room-temperature stable PCR premix, and automated protein synthesis/purification equipmentDevelopment of numerous world-first and Asia-first innovative products, including 384-oligo simultaneous automatic synthesizer, room-temperature stable PCR premix, and automated protein synthesis/purification equipment
- Global market competitiveness in supplying molecular diagnostic products to over 90 countries worldwide, contributing to novel infectious disease responseGlobal market competitiveness in supplying molecular diagnostic products to over 90 countries worldwide, contributing to novel infectious disease response
- Possession of proprietary supramolecular siRNA nanostructure SAMiRNA™ platform technology, overcoming limitations of existing siRNA therapeuticsPossession of proprietary supramolecular siRNA nanostructure SAMiRNA™ platform technology, overcoming limitations of existing siRNA therapeutics
- Intellectual property-centric management, investing over 30% of annual revenue in R&D and securing over 630 domestic and international patentsIntellectual property-centric management, investing over 30% of annual revenue in R&D and securing over 630 domestic and international patents
- Successful commercialization and global healthcare market entry of the anti-obesity lactic acid bacterium BNR17® through its subsidiary AcebiomeSuccessful commercialization and global healthcare market entry of the anti-obesity lactic acid bacterium BNR17® through its subsidiary Acebiome
- Development and dissemination of next-generation automated molecular diagnostic equipment, ExiStation™ FA 96/384, automating the entire process from nucleic acid extraction to amplification and analysisDevelopment and dissemination of next-generation automated molecular diagnostic equipment, ExiStation™ FA 96/384, automating the entire process from nucleic acid extraction to amplification and analysis
- Establishment of a foundation for diagnosing and treating various diseases, including cancer and cardiovascular diseases, through miRNA library and application researchEstablishment of a foundation for diagnosing and treating various diseases, including cancer and cardiovascular diseases, through miRNA library and application research
- Target Industrie
- Life science research and development sectorLife science research and development sector
- Molecular diagnostics market (diagnosis of infectious diseases, viral diseases, cancer, tuberculosis, STDs, respiratory diseases)Molecular diagnostics market (diagnosis of infectious diseases, viral diseases, cancer, tuberculosis, STDs, respiratory diseases)
- New drug research and development (development of RNAi therapeutics, treatments for intractable diseases like fibrosis and Alzheimer's disease)New drug research and development (development of RNAi therapeutics, treatments for intractable diseases like fibrosis and Alzheimer's disease)
- Healthcare and functional food industry (probiotic products)Healthcare and functional food industry (probiotic products)
- Cosmetics industry (hair loss relief functional cosmetics)Cosmetics industry (hair loss relief functional cosmetics)
- Food safety testing (foodborne pathogens, GMOs, food allergen analysis)Food safety testing (foodborne pathogens, GMOs, food allergen analysis)
- Animal and plant disease diagnostics sectorsAnimal and plant disease diagnostics sectors
- Major Markets
- AfricaAfrica
- South Korea, Japan, Mexico, Iraq, Indonesia, ChinaSouth Korea, Japan, Mexico, Iraq, Indonesia, China
- Europe, TurkeyEurope, Turkey
- United States, CanadaUnited States, Canada
- Brazil, ColombiaBrazil, Colombia
- Certifications/Patents
- Over 630 domestic and international patent registrations and applicationsOver 630 domestic and international patent registrations and applications
- Acquisition of domestic patent for molecular diagnostic platform technology capable of simultaneous nucleic acid extraction and gene amplificationAcquisition of domestic patent for molecular diagnostic platform technology capable of simultaneous nucleic acid extraction and gene amplification
- Possession of multiple patents related to supramolecular siRNA nanostructure SAMiRNA™Possession of multiple patents related to supramolecular siRNA nanostructure SAMiRNA™
- Securing patents related to miRNA library and application researchSecuring patents related to miRNA library and application research
- Patent application for an automatic dispensing device and a sample automatic analysis system equipped therewith (related to ExiStation™ 96 FA)Patent application for an automatic dispensing device and a sample automatic analysis system equipped therewith (related to ExiStation™ 96 FA)
- US patent registrations for double-helix oligonucleotide constructs and polymerase chain reaction systemsUS patent registrations for double-helix oligonucleotide constructs and polymerase chain reaction systems
- Possession of patents related to the anti-obesity lactic acid bacterium BNR17®Possession of patents related to the anti-obesity lactic acid bacterium BNR17®
- Asia's first acquisition of the highest CE-IVD, List A grade for HIV, HBV, HCV viral load quantification kitsAsia's first acquisition of the highest CE-IVD, List A grade for HIV, HBV, HCV viral load quantification kits
- World's first WHO Emergency Use Authorization List (EUAL) listing for Zika virus diagnostic kitsWorld's first WHO Emergency Use Authorization List (EUAL) listing for Zika virus diagnostic kits
- WHO Prequalification (PQ) acquisition for AIDS quantitative RT-PCR kitsWHO Prequalification (PQ) acquisition for AIDS quantitative RT-PCR kits
- Acquisition of GH Mark quality certification for major products including Exicycler™96Acquisition of GH Mark quality certification for major products including Exicycler™96
- Selected as a 'Venture Billion-won Company' in 2021 and awarded the '100 Million Dollar Export Tower' on the 58th Trade DaySelected as a 'Venture Billion-won Company' in 2021 and awarded the '100 Million Dollar Export Tower' on the 58th Trade Day
- Selected as a Next-Generation World-Class Product (ExiProgen™, ExiStation™, Exicycler™ 96)Selected as a Next-Generation World-Class Product (ExiProgen™, ExiStation™, Exicycler™ 96)
- Grand Prize in the Korea New Drug Award for Technology Innovation and Grand Prize in the SME Intellectual Property Management Best Practices ContestGrand Prize in the Korea New Drug Award for Technology Innovation and Grand Prize in the SME Intellectual Property Management Best Practices Contest
Introduction
Location
71 Techno 2-ro, Yuseong District, Daejeon, South Korea
클릭하여 위치 살펴보기
